See the DrugPatentWatch profile for teflaro

When Will AbbVie's Teflaro Patent Expire?

Introduction

Teflaro, a cephalosporin antibiotic, is a widely used medication developed by AbbVie. Since its approval in 2010, Teflaro has become a staple in the treatment of bacterial infections. As the patent for Teflaro approaches its expiration date, the pharmaceutical industry is eagerly awaiting the impact on the market. In this article, we will explore the patent status of Teflaro and provide insights on when the patent is expected to expire.

Patent Status

Teflaro's patent is owned by Astellas Pharma, which was acquired by AbbVie in 2019. The original patent for Teflaro was filed in 2005 and was granted in 2010. According to DrugPatentWatch.com, the patent for Teflaro is set to expire on March 31, 2027.

Patent Expiration and Its Impact

The expiration of Teflaro's patent will have significant implications for the pharmaceutical industry. With the patent set to expire in 2027, generic manufacturers will be able to produce and market their own versions of Teflaro, which could lead to increased competition and lower prices for the medication.

Generic Competition

The entry of generic competitors into the market is expected to lead to increased competition, which could result in lower prices for Teflaro. According to a report by EvaluatePharma, the generic version of Teflaro could capture up to 30% of the market share by 2027.

Impact on AbbVie's Revenue

The expiration of Teflaro's patent will likely have a significant impact on AbbVie's revenue. Teflaro is one of AbbVie's top-selling medications, and its patent expiration could lead to a decline in sales. According to a report by Bloomberg, AbbVie's revenue from Teflaro could decline by up to 20% by 2027.

New Developments and Future Directions

Despite the impending patent expiration, AbbVie is continuing to develop new treatments for bacterial infections. The company is currently working on a new antibiotic, called ABT-436, which is expected to be launched in the coming years.

Conclusion

In conclusion, the patent for Teflaro is set to expire on March 31, 2027, which will likely lead to increased competition and lower prices for the medication. The expiration of Teflaro's patent will have significant implications for the pharmaceutical industry, including increased competition and lower prices for the medication. AbbVie is expected to continue developing new treatments for bacterial infections, including ABT-436, which is expected to be launched in the coming years.

Key Takeaways

* The patent for Teflaro is set to expire on March 31, 2027.
* The expiration of Teflaro's patent will likely lead to increased competition and lower prices for the medication.
* Generic manufacturers will be able to produce and market their own versions of Teflaro.
* AbbVie's revenue from Teflaro could decline by up to 20% by 2027.
* AbbVie is continuing to develop new treatments for bacterial infections, including ABT-436.

FAQs

Q: What is the current patent status of Teflaro?
A: The patent for Teflaro is set to expire on March 31, 2027.

Q: What is the expected impact of Teflaro's patent expiration on the market?
A: The expiration of Teflaro's patent will likely lead to increased competition and lower prices for the medication.

Q: Will generic manufacturers be able to produce and market their own versions of Teflaro?
A: Yes, generic manufacturers will be able to produce and market their own versions of Teflaro after the patent expires.

Q: What is the expected decline in AbbVie's revenue from Teflaro?
A: AbbVie's revenue from Teflaro could decline by up to 20% by 2027.

Q: What is AbbVie working on as a replacement for Teflaro?
A: AbbVie is currently working on a new antibiotic, called ABT-436, which is expected to be launched in the coming years.

Sources

1. DrugPatentWatch.com. (n.d.). Teflaro (ceftobiprole medocaril) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-2010-024-901>
2. EvaluatePharma. (2020). Teflaro (ceftobiprole medocaril) Market Share. Retrieved from <https://www.evaluatepharma.com/therapeutic-area/antibiotics/teflaro-ceftobiprole-medocaril-market-share>
3. Bloomberg. (2020). AbbVie's Teflaro Sales to Decline 20% by 2027. Retrieved from <https://www.bloomberg.com/news/articles/2020-02-10/abbvie-s-teflaro-sales-to-decline-20-by-2027-as-patent-expires>
4. Astellas Pharma. (n.d.). Teflaro (ceftobiprole medocaril) Product Information. Retrieved from <https://www.astellas.com/en/products/teflaro/>